The history of Viagra presents a challenging picture for shareholders. While the initial release generated substantial profits, the lapse of its patent opened the floodgates to off-brand versions, dramatically eroding sales. This presents a particular dilemma for pharmaceutical companies banking on related blockbuster medications, suggesting that a

The story of Viagra, and its developer copyright, presents a intriguing case study for investors. Initially a blockbuster drug, yielding billions in sales , its intellectual property lapse created a flood of lower-priced alternatives , significantly eroding its market share . While specific firms may seek to capitalize on male sexual dysfunction, t